Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 36.70
+1.95 (5.61%)
Sep 8, 2026, 12:50 PM CST
Medigen Biotechnology Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 943.9 | 1,324 | 1,388 | 2,223 | 2,041 | 2,145 |
Short-Term Investments | 1,780 | 1,161 | 1,185 | 2,364 | 3,040 | 800 |
Trading Asset Securities | 0.31 | 0.31 | 0.59 | 0.49 | 54.23 | 53.6 |
Cash & Short-Term Investments | 2,724 | 2,485 | 2,574 | 4,588 | 5,135 | 2,998 |
Cash Growth | 10.63% | -3.44% | -43.90% | -10.67% | 71.28% | 32.62% |
Accounts Receivable | 255.15 | 277.39 | 286.07 | 328.89 | 398.31 | 800.22 |
Other Receivables | 64.41 | 69.79 | 87.61 | 124.72 | 66.37 | 35.46 |
Receivables | 319.55 | 347.18 | 373.67 | 453.61 | 464.69 | 835.68 |
Inventory | 713.87 | 581.27 | 645.06 | 546.91 | 692.62 | 752.87 |
Prepaid Expenses | 61.1 | 27.58 | 22.76 | 33.61 | 382.35 | 99.59 |
Other Current Assets | 31.66 | 45.71 | 46.09 | 86.4 | 57.93 | 231.96 |
Total Current Assets | 3,850 | 3,487 | 3,661 | 5,708 | 6,733 | 4,918 |
Property, Plant & Equipment | 2,021 | 1,867 | 1,981 | 2,043 | 2,198 | 2,189 |
Long-Term Investments | 463.68 | 480.78 | 640.35 | 292.87 | 307.33 | 363.71 |
Goodwill | 76.18 | 76.18 | 76.18 | 76.18 | 76.18 | 76.18 |
Other Intangible Assets | 14.58 | 18.06 | 24.18 | 30.36 | 36.9 | 48.08 |
Long-Term Deferred Tax Assets | 193.87 | 204.58 | 253.21 | 327.5 | 480.94 | 522.18 |
Other Long-Term Assets | 281.73 | 47.18 | 74.12 | 49.1 | 150.42 | 81.75 |
Total Assets | 6,902 | 6,181 | 6,710 | 8,527 | 9,982 | 8,199 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 90.92 | 98.59 | 125.29 | 122.57 | 185.01 | 163.94 |
Short-Term Debt | 130.6 | 169.6 | 229.8 | 402.6 | 328 | 300 |
Current Portion of Long-Term Debt | 47.55 | 28.6 | 47.35 | 1,728 | 28.86 | 21.34 |
Current Portion of Leases | 26.83 | 17.93 | 22 | 17.32 | 13.13 | 3.32 |
Current Income Taxes Payable | 8.15 | 12.66 | 12.73 | 24.63 | 22.99 | - |
Current Unearned Revenue | 155.12 | 161 | 231.23 | 135 | 130.4 | 244.42 |
Other Current Liabilities | 224.07 | 256.29 | 256.82 | 349.37 | 343.94 | 331.89 |
Total Current Liabilities | 683.23 | 744.65 | 925.22 | 2,780 | 1,052 | 1,065 |
Long-Term Debt | 1,102 | 421.32 | 411.25 | 449.1 | 2,129 | 470.77 |
Long-Term Leases | 380.87 | 273.81 | 308 | 267.53 | 275.32 | 196.64 |
Pension & Post-Retirement Benefits | 1.2 | 0.6 | 3.61 | 9.16 | 10.69 | 10.83 |
Long-Term Deferred Tax Liabilities | 14.42 | 14.06 | 14.08 | 14.15 | 14.24 | 14.35 |
Other Long-Term Liabilities | 10.12 | 10.12 | 10.28 | 10.28 | 29.53 | 15.89 |
Total Liabilities | 2,191 | 1,465 | 1,672 | 3,530 | 3,511 | 1,773 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1,393 | 1,393 | 1,393 | 1,393 | 1,394 | 1,394 |
Additional Paid-In Capital | 225.81 | 668.55 | 536.79 | 968.14 | 1,562 | 1,109 |
Retained Earnings | -132.16 | -461.46 | -352.66 | -747.51 | -727.98 | -52.82 |
Comprehensive Income & Other | -10.03 | -50.66 | 4.69 | -22.45 | -34.12 | -54.96 |
Total Common Equity | 1,477 | 1,549 | 1,582 | 1,592 | 2,194 | 2,394 |
Minority Interest | 3,234 | 3,167 | 3,456 | 3,405 | 4,277 | 4,032 |
Shareholders' Equity | 4,710 | 4,716 | 5,038 | 4,997 | 6,471 | 6,426 |
Total Liabilities & Equity | 6,902 | 6,181 | 6,710 | 8,527 | 9,982 | 8,199 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,687 | 911.25 | 1,018 | 2,865 | 2,774 | 992.07 |
Net Cash (Debt) | 1,037 | 1,574 | 1,555 | 1,723 | 2,361 | 2,006 |
Net Cash Growth | -31.74% | 1.21% | -9.72% | -27.03% | 17.68% | 85.87% |
Net Cash Per Share | 7.44 | 11.30 | 11.16 | 12.36 | 16.97 | 14.44 |
Filing Date Shares Outstanding | 139.31 | 139.31 | 139.31 | 139.35 | 139.45 | 139.36 |
Total Common Shares Outstanding | 139.31 | 139.31 | 139.31 | 139.35 | 139.45 | 139.36 |
Working Capital | 3,167 | 2,742 | 2,736 | 2,928 | 5,681 | 3,853 |
Book Value Per Share | 10.60 | 11.12 | 11.36 | 11.42 | 15.73 | 17.18 |
Tangible Book Value | 1,386 | 1,455 | 1,482 | 1,485 | 2,081 | 2,270 |
Tangible Book Value Per Share | 9.95 | 10.45 | 10.64 | 10.66 | 14.92 | 16.29 |
Land | 330.29 | 330.29 | 330.29 | 330.29 | 354.04 | 354.04 |
Buildings | 1,479 | 1,477 | 1,468 | 1,465 | 1,506 | 1,500 |
Machinery | 1,260 | 1,265 | 1,233 | 1,266 | 1,240 | 1,178 |
Construction In Progress | 107.21 | - | 2.57 | 21.37 | 14.54 | 4.7 |
Leasehold Improvements | 9.15 | 9.54 | 9.35 | 3.34 | 3.03 | 2.55 |